OpenBU

Measurement of Treatment Adherence with Antipsychotic Agents in Patients with Schizophrenia

OpenBU

Show simple item record

dc.contributor.author Ren, Xinhua S en_US
dc.contributor.author Herz, Lawrence en_US
dc.contributor.author Qian, Shirley en_US
dc.contributor.author Smith, Eric en_US
dc.contributor.author Kazis, Lewis E en_US
dc.date.accessioned 2012-01-11T23:12:11Z
dc.date.available 2012-01-11T23:12:11Z
dc.date.issued 2009-10-12 en_US
dc.identifier.citation Ren, Xinhua S, Lawrence Herz, Shirley Qian, Eric Smith, Lewis E Kazis. "Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia" Neuropsychiatric Disease and Treatment 5: 491-498. (2009) en_US
dc.identifier.issn 1178-2021 en_US
dc.identifier.uri http://hdl.handle.net/2144/3318
dc.description.abstract The importance of medication adherence in sustaining control of schizophrenic symptoms has generated a great deal of interest in comparing levels of treatment adherence with different antipsychotic agents. However, the bulk of the research has yielded results that are often inconsistent. In this prospective, observational study, we assessed the measurement properties of 3 commonly used, pharmacy-based measures of treatment adherence with antipsychotic agents in schizophrenia using data from the Veterans Health Administration during 2000 to 2005. Patients were selected if they were on antipsychotics and diagnosed with schizophrenia (N = 18,425). A gap of ≥30 days (with no filled index medication) was used to define discontinuation of treatment as well as medication "episodes," or the number of times a patient returned to the same index agent after discontinuation of treatment within a 1-year period. The study found that the 3 existing measures differed in their approaches in measuring treatment adherence, suggesting that studies using these different measures would generate different levels of treatment adherence across antipsychotic agents. Considering the measurement problems associated with each existing approach, we offered a new, medication episode-specific approach, which would provide a fairer comparison of the levels of treatment adherence across different antipsychotic agents. en_US
dc.description.sponsorship Center for the Assessment of Pharmaceutical Practices (CAPP) at Boston University School of Public Health; Center for Health Quality; Outcomes; Economic Research at Bedford VA Medical Center; Unrestricted educational grant from Eli Lilly and Company en_US
dc.language.iso en en_US
dc.publisher Dove Medical Press en_US
dc.rights Copyright 2009 Ren et al, publisher and licensee Dove Medical Press Ltd. en_US
dc.subject Medication adherence en_US
dc.subject Antipsychotic agents en_US
dc.subject Schizophrenia en_US
dc.title Measurement of Treatment Adherence with Antipsychotic Agents in Patients with Schizophrenia en_US
dc.type article en_US
dc.identifier.pubmedid 19851516 en_US
dc.identifier.pmcid 2762365 en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search OpenBU


Browse

Deposit Materials

Statistics